Volume 36, Issue 6 pp. 823-830
RESEARCH ARTICLE

Therapeutic plasma exchange for life-threatening pediatric disorders

Jean-Sebastien Diana MD

Corresponding Author

Jean-Sebastien Diana MD

Hôpital Necker Enfants Malades, Paris, France

Université de Paris, Paris, France

Correspondence

Jean-Sebastien Diana, Biotherapy Departement, Hôpital Necker Enfants Malades, 149 rue de Sèvres, 75015 Paris, France.

Email: [email protected]

Search for more papers by this author
Sandra Manceau PhD

Sandra Manceau PhD

Hôpital Necker Enfants Malades, Paris, France

Université de Paris, Paris, France

Search for more papers by this author
Tioka Rabeony BSc

Tioka Rabeony BSc

Institut Imagine, Paris, France

Search for more papers by this author
Caroline Elie MD, PhD

Caroline Elie MD, PhD

Université de Paris, Paris, France

Institut Imagine, Paris, France

Search for more papers by this author
Valerie Jolaine MD, PhD

Valerie Jolaine MD, PhD

Université de Paris, Paris, France

Institut Imagine, Paris, France

Search for more papers by this author
Sandrine Zamora BSc

Sandrine Zamora BSc

Hôpital Necker Enfants Malades, Paris, France

Search for more papers by this author
Melodie Aubart MD

Melodie Aubart MD

Hôpital Necker Enfants Malades, Paris, France

Search for more papers by this author
Nadege Salvi MD

Nadege Salvi MD

Hôpital Necker Enfants Malades, Paris, France

Search for more papers by this author
Christine Bodemer MD, PhD

Christine Bodemer MD, PhD

Hôpital Necker Enfants Malades, Paris, France

Université de Paris, Paris, France

Search for more papers by this author
Brigitte Bader-Meunier MD

Brigitte Bader-Meunier MD

Hôpital Necker Enfants Malades, Paris, France

Search for more papers by this author
Christine Barnerias MD

Christine Barnerias MD

Hôpital Necker Enfants Malades, Paris, France

Search for more papers by this author
Franck Iserin MD

Franck Iserin MD

Hôpital Necker Enfants Malades, Paris, France

Search for more papers by this author
Christophe Chardot MD, PhD

Christophe Chardot MD, PhD

Hôpital Necker Enfants Malades, Paris, France

Université de Paris, Paris, France

Search for more papers by this author
Florence Lacaille MD

Florence Lacaille MD

Hôpital Necker Enfants Malades, Paris, France

Search for more papers by this author
Sylvain Renolleau MD, PhD

Sylvain Renolleau MD, PhD

Hôpital Necker Enfants Malades, Paris, France

Université de Paris, Paris, France

Search for more papers by this author
Remi Salomon MD, PhD

Remi Salomon MD, PhD

Hôpital Necker Enfants Malades, Paris, France

Université de Paris, Paris, France

Search for more papers by this author
Laure Joseph MD

Laure Joseph MD

Hôpital Necker Enfants Malades, Paris, France

Search for more papers by this author
Marina Cavazzana MD, PhD

Marina Cavazzana MD, PhD

Hôpital Necker Enfants Malades, Paris, France

Université de Paris, Paris, France

Institut Imagine, Paris, France

Search for more papers by this author
François Lefrere MD

François Lefrere MD

Hôpital Necker Enfants Malades, Paris, France

Search for more papers by this author
Laurent Dupic MD

Laurent Dupic MD

Hôpital Necker Enfants Malades, Paris, France

Search for more papers by this author
Marianne Delville MD, PhD

Marianne Delville MD, PhD

Hôpital Necker Enfants Malades, Paris, France

Université de Paris, Paris, France

Institut Imagine, Paris, France

Search for more papers by this author
First published: 01 September 2021
Citations: 2

Funding information: The « Assistance Publique des Hôpitaux de Paris » supports this project.

Abstract

Introduction

Therapeutic plasma exchange (TPE) is acknowledged to be an effective treatment in life-threatening pediatric disorders. Apheresis for pediatric diseases has been poorly investigated, and most studies to date featured small numbers of patients and lacked control groups. The objective of the present study was to evaluate the tolerance of TPE in pediatric patients.

Materials and Methods

A retrospective cohort study via a web-based electronic case report form including pediatric patients referred for TPE between January 2005 and December 2014.

Results

A total of 78 patients (median [range] age: 9.8 [0.53-17.93]) and 731 TPE procedures were analyzed. The indications were antibody-mediated rejection (n = 33; 42%) and desensitization therapy (n = 5; 6%) after solid organ or hematopoietic stem cell transplantation, thrombotic microangiopathy (n = 17; 22%), pediatric inflammatory diseases (n = 16; 21%), kidney diseases (n = 6; 8%), and hyperviscosity syndrome (n = 1; 1%). On average, each patient underwent six procedures during the first session [range: 1-19]. In the 2 weeks following the start of a session, 72 patients (92%) presented a total of 311 adverse events (AEs) potentially related to TPE. The risk of AEs was not related to the indication for TPE, the intensity of care, venous access, plasma substitute use, or body weight. None of the deaths was related to the TPE.

Conclusion

We studied one of the largest retrospective pediatric cohorts described to date. Our experience of TPE children's TPE feasibility concerned specific, life-threatening conditions and otherwise treatment-refractory diseases.

CONFLICT OF INTEREST

The authors declare no potential conflict of interest.

DATA AVAILABILITY STATEMENT

Raw data were generated at Institut Imagine via eCRF database (CleanWEB, Telemedicine Technologies Boulogne Billancourt, France; https://www.tentelemed.com/la-solution-cleanweb/?lang=en). Derived data supporting the findings of this study are available from the corresponding author on request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.